Post UMR, there are more demands on both the operations and funding challenges related to OTC derivatives. Firms world-wide have new competing priorities, whether they are sellside or buyside: optimize collateral and focus on resource savings or transform collateral to improve returns.

Join other front office, risk management, and trading professionals discuss these challenging times and the collateral optimization and funding opportunities that can both save costs and increase performance.